|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A phase Ⅱ trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer显示文摘 | Dickler MN Rugo HS Eberle CA | 2008 | Clin Cancer Res2008，14，： | 1 |
| 2 | A randomized,phase Ⅱ,three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer显示文摘 | Rugo HS Campone M Amadori D | 2013 | Breast Cancer Res Treat2013，139，2： | 1 |
| 3 | TBCRC 001: randomized phase II study of cetuximab in combina- tion with carboplatin in stage IV triple-negative breast can- cer 显示文摘 | CAREY LA RUGO HS MARCOM PK | 2012 | Journal of Clinical Ontology Official Journal of the American Society of Clinical Oncology2012，30，30： | 1 |
| 4 | TBCRC 001:EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer显示文摘 | Carey LA Rugo HS Marcom PK | 2008 | J Clin Oncol2008，26，151： | 1 |
| 5 | Phase Ⅰ trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmaeokinetie and clinical results 显示文摘 | Rugo HS Herbst RS Liu G | 2005 | Clin Oncol2005，23，24： | 1 |
| 6 | EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative breast cancer显示文摘 | Carey LA Rugo HS Marcom PK | 2008 | J Clin Oncol2008，26，15： | 1 |
| 7 | Bevacizumab in the treatment of breast cancer:rationale and current data显示文摘 | | 2004 | Oncologist2004，1，9： | 1 |
| 8 | Immune microenviron-ments in solid tumors:new targets for therapy 显示文摘 | Shiao SL Ganesan AP Rugo HS | 2011 | Genes Dev2011，25，24： | 1 |
| 9 | Phase II study of the an- tibody drug conjugate trastuzumab- DM1 for the treatment of hu- man epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2--directed therapy显示文摘 | Burris HA 3rd Rugo HS Vukelja SJ | 2011 | J Clin Oncol2011，29，4： | 1 |
| 10 | Phase II study of suni- tinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane 显示文摘 | Burstein H J Elias AD Rugo HS | 2008 | J Clin Oncol2008，26，11： | 1 |
| 11 | Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2- directed therapy 显示文摘 | BURRIS HR RUGO HS VUKLJA SJ et o1 | 2011 | J Clin Oncol2011，29，4： | 1 |
| 12 | TBCRC 001 : randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer 显示文摘 | Carey LA Rugo HS Marcom PK | 2012 | J Clin Oncol2012，30，21： | 1 |
| 13 | Phase II study of sunitinib malate,an oral multitargeted tyrosine kinase inhibitor,in patients with metastatic breast cancer previously treated with an anthracycline and a taxane显示文摘 | Burstein H J Elias AD Rugo HS | 2008 | J Clin Oncol2008，26，11： | 1 |
| 14 | Phase Ⅲ trial of capecitabine (Xeloda○ R) plus bevacizumab (AvastinTM) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane显示文摘 | Miller KD Rugo HS Cobleigh MA | 2002 | Breast Cancer Res Treat2002，76，1： | 1 |
| 15 | The role of angiogenesis inhibition in the treatment of breast cancer显示文摘 | Sledge GW Rugo HS Burstein HJ | 2006 | Clin Adv Hematol Oncol2006，21，10： | 1 |
| 16 | Randomized, placebo- controlled, double-blind, phase Ⅱ study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer显示文摘 | Rugo HS Stopeck AT Joy AA | 2011 | J Clin Oncol2011，29，18： | 1 |
| 17 | Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER显示文摘 | Brufsky AM Mayer M Rugo HS | 2011 | Clin Cancer Res2011，17，14： | 1 |
| 18 | Leukocyte composition of human breast cancer 显示文摘 | Ruffell B Au A Rugo HS | 2012 | Proceedings of the National A- cademy of Sciences2012，109，8： | 1 |
| 19 | Phase II study of sanitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane 显示文摘 | BURSTEIN HJ ELIAS AD RUGO HS | 2008 | J Clin Oncol2008，26，11： | 1 |
| 20 | Phase Ⅱ study of sunitinib malate,an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracyeline and a taxane显示文摘 | Burstein HJ Elias AD Rugo HS | 2008 | J Clin Oncol2008，26，11： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员